The use of erlotinib in daily practice: A study on adherence and patients' experiences

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Timmers, Lonneke ^a   Boons, Christel C L M ^a   Mangnus, Dirk ^a   Moes, Josee E ^a   Swart, Eleonora L ^a   Boven, Epie ^a   Smit, Egbert F ^a   Hugtenburg, Jacqueline G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; ATTITUDE TO ILLNESS; CLINICAL PROTOCOL; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG USE; LUNG NON SMALL CELL CANCER; OBSERVATIONAL STUDY; PATIENT ATTITUDE; PERSONAL EXPERIENCE; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; ATTITUDE TO HEALTH; BLOOD; CULTURAL ANTHROPOLOGY; DOSE RESPONSE; DRUG MONITORING; FOLLOW UP; HUMAN; INFORMED CONSENT; LUNG TUMOR; METHODOLOGY; MULTICENTER STUDY (TOPIC); PATIENT; PATIENT COMPLIANCE; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENTS; ATTITUDE TO HEALTH; CARCINOMA, NON-SMALL-CELL LUNG; CULTURE; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FOLLOW-UP STUDIES; HUMANS; INFORMED CONSENT; LUNG NEOPLASMS; MEDICATION ADHERENCE; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; PATIENTS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; QUINAZOLINES; RESEARCH DESIGN;

EID: 79959761280     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-284     Document Type: Article

References (45)

1. Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, Morris R, Price M. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006, 17(2):205-210.
2. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15(1):110-115.
3. Kruse GB, Amonkar MM, Smith G, Skonieczny DC, Stavrakas S. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm 2008, 14(9):844-857.
4. Twelves CJ. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer 2006, 6(4):278-287. 10.3816/CCC.2006.n.046, 17241512.
5. Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 2006, 10/28(14):2381-8. 95(1):27-34.
6. Sabaté E. Adherence to long-term therapies Evidence for action 2003, Geneva: World Health Organization.
7. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer 1993, 71(10 Suppl):3441-3449.
8. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11(1):44-47. 10.1111/j.1524-4733.2007.00213.x, 18237359.
9. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59(1):56-66. 10.3322/caac.20004, 19147869.
10. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002, 94(9):652-661.
11. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009, 15(9):728-740.
12. Klein CE, Kastrissios H, Miller AA, Hollis D, Yu D, Rosner GL, Grinblatt DL, Larson RA, Ratain MJ. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 2006, 57(2):199-206. 10.1007/s00280-005-0023-6, 16158312.
13. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993, 11(6):1189-1197.
14. Nilsson JLG, Andersson K, Bergkvist A, Bjorkman I, Brismar A, Moen J. Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care (Engl) 2006, 15(3):235-237.
15. Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, Martiat P, Mineur P, van Eygen K, MacDonald K, De Geest S, Altrecht T, Abraham I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113(22):5401-5411. 10.1182/blood-2008-12-196543, 19349618.
16. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003, 21(4):602-606. 10.1200/JCO.2003.07.071, 12586795.
17. Ruddy KJ, Partridge AH. Adherence with adjuvant hormonal therapy for breast cancer. Ann Oncol 2009, 20(3):401-402.
18. Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kazlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28(14):2381-2388. 10.1200/JCO.2009.26.3087, 20385986.
19. Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010, 26(12):2861-2869. 10.1185/03007995.2010.533648, 21062136.
20. McAndrew LM, Musumeci-Szabo TJ, Mora PA, Vileikyte L, Burns E, Halm EA, Leventhal EA, Leventhal H. Using the common sense model to design interventions for the prevention and management of chronic illness threats: from description to process. Br J Health Psychol 2008, 13:195-204. 10.1348/135910708X295604, 18331667.
21. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res 2006, 60:631-637. 10.1016/j.jpsychores.2005.10.020, 16731240.
22. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychology and Health 1999, 14:1-24.
23. Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr 2007, 1/45(3):334-341.
24. Jonsdottir H, Friis S, Horne R, Pettersen KI, Reikvam A, Andreassen OA. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand 2009, 119(1):78-84. 10.1111/j.1600-0447.2008.01279.x, 18983630.
25. Mardby AC, Akerlind I, Jorgensen T. Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns 2007, 69(1-3):158-164.
26. Menckeberg TT, Bouvy ML, Bracke M, Kaptein AA, Leufkens HG, Raaijmakers JAM, et al. Beliefs about medicines predict refill adherence to inhaled corticosteroids. J Psychosom Res 2008, 64(1):47-54. 10.1016/j.jpsychores.2007.07.016, 18157999.
27. Schuz B, Marx C, Wurm S, Warner LM, Ziegelmann JP, Schwarzer R, et al. Medication beliefs predict medication adherence in older adults with multiple illnesses. J Psychosom Res 2011, 70(2):179-187. 10.1016/j.jpsychores.2010.07.014, 21262421.
28. Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011, 35(5):626-630. 10.1016/j.leukres.2010.10.017, 21095002.
29. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 2009, 101(23):1624-1632. 10.1093/jnci/djp386, 2786917, 19920223.
30. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010, 362(10):865-869. 10.1056/NEJMp0911494, 3031980, 20220181.
31. Roche Registration Ltd Tarceva: European Public Assessment Report Product Information. Annex I: Summary of product characteristics 2010, European Medicines Agency, Roche Registration Ltd.
32. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19(13):3267-3279.
33. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008, 26(7):1119-1127. 10.1200/JCO.2007.13.1128, 18309947.
34. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol 2004, 22(16):3238-3247. 10.1200/JCO.2004.11.057, 15310767.
35. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007, 13(13):3913-3921. 10.1158/1078-0432.CCR-06-2610, 17606725.
36. Lu JF, Eppler SM, Wolf J, Hamilton M, Rakhit A, Bruno R, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther 2006, 80(2):136-145. 10.1016/j.clpt.2006.04.007, 16890575.
37. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007, 6(3):432-438. 10.4161/cbt.6.3.3763, 17312388.
38. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006, 12(7 Pt 1):2166-2171.
39. Ling J, Fettner S, Lum BL, Riek M, Rakhit A. Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anticancer Drugs 2008, 19(2):209-216. 10.1097/CAD.0b013e3282f2d8e4, 18176118.
40. Butler JA, Peveler RC, Roderick P, Horne R, Mason JC. Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation 2004, 77(5):786-789. 10.1097/01.TP.0000110412.20050.36, 15021850.
41. Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): a new measurement tool for audit and research. Qual Health Care 2001, 10(3):135-140. 10.1136/qhc.0100135, 1743429, 11533420.
42. Aaronson NK, Muller M, Essink-Bot ML, Fekkes M, Sanderman R, te Velde A, Verrips E. Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations. J Clin Epidemiol 1998, 51(11):1055-1068. 10.1016/S0895-4356(98)00097-3, 9817123.
43. Hurst NP, Ruta DA, Kind P. Comparison of the MOS short form-12 (SF12) health status questionnaire with the SF36 in patients with rheumatoid arthritis. Br J Rheumatol 1998, 37(8):862-869. 10.1093/rheumatology/37.8.862, 9734677.
44. Olivieri NF, Matsui D, Hermann C, Koren G. Compliance assessed by the Medication Event Monitoring System. Arch Dis Child 1991, 66:1399-1402. 10.1136/adc.66.12.1399, 1793394, 1776885.
45. Denhaerynck K, Schäfer-Keller P, Young J, Steiger J, Bock A, De Geest S. Examining assumptions regarding valid electronic monitoring of medication therapy: development of a validation framework and its application on a European sample of kidney transplant patients. BMC Medical Research Methodology 2008, 8:5. 10.1186/1471-2288-8-5, 2275282, 18284675.